[Clinical use of new cephalosporins for severe infections in internal medicine].
Our clinical experience with new antibiotics giving special consideration to the individual cephalosporin groups is discussed. Although newer cephalosporins from cefamandol and cefoxitin to cefotiam and cefoperazon already showed increased effectiveness (for example, cefoxitin in bacteroides infection) in comparison to older ones, the real breakthrough regarding enterobacteriaceae was only made with cephalosporins of the cefotaxime group. This group's main indication is non-specific initial therapy of severe nosocomial infections, especially processes in which the presence of resistant enterobacteriaceae must be assumed. Because of its broad spectrum of action, cefotaxime can to a large extent replace the combinations with aminoglycosides which were used previously. When required, cefotaxime proves to be a good partner for combinations with pseudomonas antibiotics.
D001442:Bacteroides Infections / Q000188:drug therapy; D002439:Cefotaxime / Q000627:therapeutic use; D002440:Cefoxitin / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013329:Structure-Activity Relationship
D002511:Cephalosporins; D005839:Gentamicins; D002440:Cefoxitin; D002439:Cefotaxime
Klinischer Einsatz neuer Cephalosporine bei schweren Infektionen in der inneren Medizin.